Algorae Pharmaceuticals says its new AI-168 drug candidate shows early potential to improve on treatments to protect the heart from cardiovascular stressors.
Men with cardiovasculardisease risk factors, including obesity, face brain health decline a decade earlier-;from their mid 50s to mid 70s-;than similarly affected women who are most susceptible ...